Literature DB >> 6601240

Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.

M Schapira, L D Silver, C F Scott, A H Schmaier, L J Prograis, J G Curd, R W Colman.   

Abstract

Patients with hereditary angioedema lack C-1 inhibitor, a plasma alpha 2-glycoprotein that inhibits both the proteolytic action of C1, the activated first component of the complement system, and the activity of components of the contact phase of coagulation: kallikrein, factor XIa, and factor XIIa. Such patients have been shown to have low levels of C4 and C2, the natural substrates for C-1, but the levels were not correlated with the presence of symptoms. We studied three patients with angioedema for evidence of activation of the contact system and found that during a symptomatic period they had decreased levels of prekallikrein, a substrate for the activated forms of factor XII, and reductions in high-molecular-weight kininogen, a substrate for plasma kallikrein. These observations suggest that zymogens of the contact system are activated during attacks of hereditary angioedema and that some of the clinical manifestations may be mediated through products of this pathway, such as kinins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601240     DOI: 10.1056/NEJM198305053081802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  40 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

3.  The hereditary angioedema syndromes.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

4.  Algodystrophy (Sudeck's syndrome) in association with hereditary angioneurotic oedema.

Authors:  C Cooper; M I Cawley
Journal:  J R Soc Med       Date:  1985-03       Impact factor: 5.344

5.  Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors.

Authors:  S M Wood; R D Mann; M D Rawlins
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-10

6.  Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits.

Authors:  Dorit Farfara; Emily Feierman; Allison Richards; Alexey S Revenko; Robert A MacLeod; Erin H Norris; Sidney Strickland
Journal:  Glia       Date:  2019-03-18       Impact factor: 7.452

7.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.

Authors:  M Cugno; J Nuijens; E Hack; A Eerenberg; D Frangi; A Agostoni; M Cicardi
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

8.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

10.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.